The Brain Trauma Indicator (BTI) works by measuring levels of two proteins, known as Ubiquitin C- terminal Hydrolase-L1 (UCH-L1) and Glial Fibrillary Acidic Protein (GFAP), that are released from the brain into the bloodstream and measured within 12 hours of head injury. The assay results obtained are used, along with other available clinical information, to aid in the evaluation of patients 18 years of age and older with suspected traumatic brain injury (Glasgow Coma Scale score 13-15). A negative assay result is associated with the absence of acute intracranial lesions visualized on a head computed tomography (CT) scan.
Banyan Biomarkers is currently dedicating all its efforts to meet the needs and requirements of the US Department of Defense. Once we have addressed those needs, we will then focus our attention to hospital laboratories and physicians. If you are interested in being a part of our mailing list for updates, please email us at email@example.com.
For In Vitro Diagnostic Use